The roll-out of China’s centralized generic drug procurement plan will take place on revised terms, it is reported.
A report from Bloomberg, which itself quotes the 21st Business Herald, says that the bulk buying program for generics, which had its pilot in 11 cities last December, will go nationwide on significantly altered terms.
Rather than selecting one winner for each tender, authorities will pick not just the lowest bidder, but also two other firms willing to match its price.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze